Iron storage indices and risk of bacterial infections in hemodialysis patients

Hemodialysis International

Volumn 8, Issue 3, 2004, Pages 226-232

  Teehan, Geoffrey S ^a   Ruthazer, Robin ^a   Balakrishnan, Vaidyanathapuram S ^a   Snydman, David ^a   Jaber, Bertrand L ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Epidemiology; Ferritin; Pneumonia; Sepsis; Transferrin saturation

Indexed keywords

FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; IRON DEXTRAN; TRANSFERRIN;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE CALCULATION; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; INFECTION RISK; IRON DEFICIENCY; IRON STORAGE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; TRANSFERRIN BLOOD LEVEL; VEIN CATHETERIZATION;

EID: 22644441977     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1492-7535.2004.01100.x     Document Type: Article

References (34)

1. Macdougall I. Strategies for iron supplementation: Oral versus intravenous. Kidney Int Suppl. 1999; 69:S61-S66.
2. Sunder-Plassmann G, Hörl W. Comparative look at intravenous iron agents: Pharmacology, efficacy, and safety of iron dextran, iron saccharate, and ferric gluconate. Semin Dial. 1999; 12:243-248.
3. Rosenlof K, Kivivuori SM, Gronhagen-Riska C, Teppo AM, Slimes MA. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol. 1995; 43(4): 249-255.
4. Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, van Landuyt HW. Iron overload in hemodialysis patients increases the risk of bacteremia: A prospective study. Nephrol Dial Transplant. 1990; 5(2): 130-134.
5. Nomura S, Osawa G, Karai M. Treatment of a patient with end-stage renal disease, severe iron overload and ascites by weekly phlebotomy combined with recombinant human erythropoietin. Nephron. 1990; 55(2):210-213.
6. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: Incidence, risk factors, and prognosis. Kidney Int. 1999; 55(3):1081-1090.
7. Hoen B, Paul-Dauphin ADH, Kessler M. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol. 1998; 9(5):869-876.
8. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 2000; 58(4):1758-1764.
9. Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001; 120(6):1883-1887.
10. Eckardt KU; Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) Trial. The CREATE trial - building the evidence. Nephrol Dial Transplant. 2001; 16(Suppl 2):16-18.
11. National Kidney Foundation - Dialysis Outcomes Quality Initiative. Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. New York: National Kidney Foundation, Inc.; 1997.
12. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant. 1995; 10(3):377-381.
13. Arbo MD, Snydman DR. Influence of blood cultures on antibiotic choice in the treatment of bacteremia. Arch Intern Med. 1994; 154(23):2641-2645.
14. USRDS Annual Data Report [Internet]. Bethesda: National Institutes of Health, Diabetes and Digestive and Kidney Diseases; 1998. Available from: http://www.usrds.org/adr_1998.htm
15. Seifert A, von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med. 1987; 65(248):1015-1024.
16. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH. Neutrophil impairment associated wit iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol. 1998; 9(4):655-663.
17. Parkkinen J, von Bonsdorff L, Peltonen S. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron administration. Nephrol Dial Transplant. 2000; 15(4):1827-1834.
18. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol. 2002; 57(6):457-461.
19. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol. 2002; 13(3):734-744.
20. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis. 1999; 34(4 Suppl 2):S47-S52.
21. Collins AJ, Li S, St. Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol. 2001; 12(11):2465-2473.
22. Cohen D, Raja RM. Erythropoietin (EPC) requirements remain high in EPO resistant patients after iron repletion. ASAIO J. 1998; 44(5):M596-M597.
23. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996; 27(2):234-238.
24. Schaefer RM, Schaefer L. Iron monitoring and supplementation: How do we achieve the best results? Nephrol Dial Transplant. 1998; 13(Suppl 2): 9-12.
25. Cook JD. Clinical evaluation of iron deficiency. Semin Hematol. 1982; 19:6-18.
26. Goldwasser P, Koutelos T, Abraham S, Avram MM. Serum ferritin, hematocrit, and mean corpuscular volume in hemodialysis. Nephron. 1994; 67(1):30-35.
27. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int. 1999; 55(5):1945-51.
28. Kirschbaum B. Hypotransferrinemia of chronically hemodialyzed patients. Artif Organs. 1999; 23(12): 1047-1054.
29. Bosticardo GM, Arnoletti F, Dapiran D, Zola P, Maneglia M, Avalle U, Gaicchino F. [Assessment of reticulocyte hemoglobin content as a guide for iron supplementation in hemodialyzed patients.] Minerva Urol Nefrol. 2000; 52(3):143-145.
30. Zupan IP, Varl J, Kovac D, Cernelc P, Mlakar U, Andoljsek D, Pretnar J, Zver S, Modic M. Indices of iron status in patients treated by chronic haemodialysis. Pflugers Arch. 2001; 442(6 Suppl. 1):R202-203.
31. Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, Dominguez-Cabrera C, Hortal-Casc L, Perez-Borges P, Vega-Diaz N, Saavedra-Santana P, Palop-Cubillo L. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis. 1999; 34(3):508-513.
32. Canziani ME, Yumiya ST, Rangel EB, Manfredi SR, Neto M, Draibe SA. Risk of bacterial infection in patients under intravenous iron therapy: Dose versus length of treatment. Artif Organs. 2001; 25(11): 866-869.
33. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol. 1996; 7(12):2654-2657.
34. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis. 1995; 26(2):292-299.